Open access

Factors Related to Graft Outcome in Pediatric Renal Transplantation: a Single Center Study

Written By

Jean Herman and Rita Van Damme-Lombaerts

Submitted: 21 October 2010 Published: 17 August 2011

DOI: 10.5772/17617

From the Edited Volume

After the Kidney Transplant

Edited by Jorge Ortiz and Jason Andre

Chapter metrics overview

2,794 Chapter Downloads

View Full Metrics

1. Introduction

Over the last decades, renal transplantation has evolved from an experimental procedure into the treatment of choice for children with end-stage renal disease. Differences in size and weight of the recipient, cause of renal failure, immune responsiveness, susceptibility to infection, pharmacokinetics of immunosuppressive drugs, and psychological aspects distinguish renal transplantation in children from adults. The longevity of an allograft is particularly important for the pediatric transplant recipient, because renal replacement therapy is necessarily a lifelong undertaking. The aim of the present study is to determine by means of a multivariable analysis the factors that significantly affect graft outcome in the paediatric transplant population. Knowledge of predictors of graft survival can be beneficial in planning the renal replacement therapy in children and improving transplantation results.

Registry studies, essentially from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) (Benfield et al., 1999; NAPRTCS, 2010) and from the United Network for Organ Sharing (UNOS) (Hwang et al., 2005), have been performed to analyse factors related to graft outcome in children. Registry studies have the advantage of being able to include large number of patients. However these studies usually involve heterogeneous populations with different pre-transplant selections, transplant procedures and post-transplant management. Therefore single center studies using a more homogeneous patient group and more uniform management protocols may be valuable in the analysis of transplant outcome. Nevertheless such single center studies using multivariable techniques to analyse transplant outcome are very scarce in paediatric renal transplantation (Vats et al., 2002).

We analysed all renal transplantations performed in children at our institution between 1980 and 2010 and included in our analysis various factors concerning recipient characteristics, donor characteristics, perioperative characteristics and post-transplant events.


2. Patients, materials and methods

2.1. Patients

The study population consisted of 151 kidney transplants performed between June 1980 and October 2010 in 135 children (81 boys and 54 girls) with mean age 10.7 years (± 4.9) at transplantation. There were 132 first grafts, 15 second grafts, 3 third grafts and 1 fourth graft.

The original disease was congenital or hereditary in 74% and acquired in 26%. Thirteen children were transplanted preemptively. Kidney came from living related donors (LRD) in 33 cases (22%) and from deceased donors (DD) in 118 cases (78%). Four children underwent combined liver-kidney transplantation.

Immunosuppression consisted of an induction with antilymphocyte antibodies and a maintenance regimen with cyclosporine A (CsA) (since December 1984), azathioprine and prednisolone. Newer immunosuppressive agents were introduced more recently: tacrolimus in 1998, mycophenolate mofetyl in 1998, basiliximab and daclizumab in 1999.

2.2. Data source

Data were retrieved from the patients’ medical files and from the archives and database of Eurotransplant. The follow-up period ended in February 2011.

2.3. Analytic variables and statistical analysis

The following variables were studied as potential factors affecting graft outcome:

Recipient characteristics: age (years), gender, height (cm), weight (kg), body surface area (BSA, m2), body mass index (BMI, kg/m2), prior transplant, primary kidney disease, peak and current panel-reactive antibody percentage (PRA), ABO blood group, CMV serological status, number of prior blood transfusions (0-5 vs. >5), native nephrectomy, dialysis modality before transplantation, dialysis duration (years), time on the waiting list (years), hypertension (defined as the use of antihypertensive medications), year of transplantation.

Donor characteristics: age, gender, height, weight, BSA, BMI, ABO group, CMV status, donor type (LRD vs. DD), cause of death for the deceased donors, serum creatinine level (mg/dl) at organ retrieval, diuresis (ml) during the last 24 hours and the last hour before organ retrieval.

Donor recipient relationships: donor/recipient age ratio, height ratio, weight ratio, BSA ratio, BMI ratio, gender mismatch, human leukocyte antigen (HLA) mismatch, ABO mismatch (all grafts were ABO compatible but one), CMV mismatch (D+/R-, D-/R+, D+/R+, D-/R-).

Organ preservation and perioperative characteristics: donor kidney preservation solution (Eurocollins (EC) vs. University of Wisconsin (UW) vs. histidine–tryptophan-ketoglutarate (HTK)), cold ischemia time (hours), warm ischemia time (minutes).

Immunosuppression: induction therapy (polyclonal vs. monoclonal vs. none) and maintenance immunosuppression at time of discharge from the initial hospitalization including use of calcineurin inhibitors and type (CsA vs. tacrolimus), use of antimetabolites and type (azathioprine vs. mycophenolate mofetyl).

Post-transplant characteristics: duration of initial transplant hospitalization (days), occurrence of delayed graft function (DGF) defined as the need for dialysis in the first week post-transplant, occurrence of acute rejection episodes, creatinine clearance (ml/min/1.73 m2) at 1 year post-transplant (calculated using the Schwartz formula: creatinine clearance = 0.55*height (cm)/plasma creatinine (mg/dl)), hypertension (defined as the use of antihypertensive medications) and its severity as reflected by the number of antihypertensive medications at 1 year post-transplant, proteinuria (>1 g/24 h) at 1 year post-transplant, hemoglobin (g/dl) at 1 year post-transplant.

Acute Rejection was defined as any rejection treatment. Acute rejection was suspected when the serum creatinine level increased to 20% above the baseline level and was biopsy proven in most cases.

Univariable analysis was performed on each of these variables using the Cox proportional hazards regression model. Variables with a p-value <0.10 in the univariable analysis were then entered into the multivariable analysis. Cox regression was applied with forward stepwise selection using likelihood-ratio tests. Variables were retained in the model at p<0.05. Acute rejection was considered as a time dependent covariate.

The hazard ratios (HR) for graft failure and corresponding 95% confidence intervals were estimated. Graft failure was defined as return to dialysis, re-transplantation or death with a functioning graft. Graft survival time was defined as the time between the date of transplantation and graft failure or the end of the study period.

Two models were constructed: one starting at the time of transplantation thus including all transplants (n=151) and one starting after the end of the first year post-transplant including transplants that functioned beyond the first year (n=140). Hypertension at 1 year, creatinine clearance at 1 year, proteinuria at 1 year (>1 g/24 h), hemoglobin at 1 year were included in the second model as additional potential predictors for graft survival after 1 year.

Patient and graft survivals were calculated with the Kaplan–Meier method.

Statistical analyses were performed using Statistica 8.1 (StatSoft Inc., Tulsa, OK., USA) and SPSS 18.0 (SPSS Inc., Chicago, IL., USA). Statistical significance was defined as p<0.05.


3. Results

3.1. Patient and graft survival

The actuarial patient survival was 97% at 1 year, 96% at 3 years, 94% at 5 years and 92% at 10 years (Figure 1). Nine patients died, three of them with a functioning graft. The cause of death was bacterial infection in four children, Pneumocystis carinii infection in one, malignant lymphoproliferative disorder in one, and a cardiovascular complication in three (two of whom died following cerebral haemorrhage and one following a myocardial infarction).

The overall actuarial graft survival was 94% at 1 year, 86% at 3 years, 80% at 5 years and 64% at 10 years (Figure 1). Mean follow-up time was 9.3 ± 6.5 years.

The actuarial graft survival at 1, 3, 5, 10 years was 94%, 90%, 83% and 68% respectively for recipients of living-related donor and 94%, 83%, 79% and 63% respectively for recipients of deceased donor (Log-Rank Test p=0.95). In children younger than 5 years the graft survival was 92% at 1 and 3 years, and 83% at 5 and 10 years; in this group the prevalence of LRD was rather high (11/24; 46%).

In total 68 grafts were lost during the study period, 9 of them during the first year post-transplant. The causes of graft loss are given in Table 1; chronic rejection being the leading cause. Non compliance was documented in 19% of the failure due to chronic rejection (9 cases). Recurrence of the initial disease was the second most frequent cause of graft failure.

The main characteristics of the study population are detailed in Table 2.

Figure 1.

Kaplan Meier plot of patient and graft survivals (n indicates the number of subjects at risk at 0, 3, 5 and 10 years).

n %
Chronic rejection4769.1
Recurrence of primary disease811.8
Death with functioning graft34.4
Infection 22.9
Technical failure22.9
Primary non-function 22.9
Polyoma nephropathy11.5
Thrombosis renal artery11.5

Table 1.

Causes of graft failure

N*Mean ± SD or nRange or %
Recipient characteristics
Age (year)10.7 ± 4.71.3-21.9
0-4 2415.9%
Gender M/F91/6059.6/40.4%
Weight (kg)20.5 ± 14.58.4-76.4
Primary Tx/ReTx132/1987.4/12.6%
Primary kiney disease
Congenital uro-nephropathy7247.7%
Hereditary nephropathy4026.5%
Acquired nephropathy3925.8%
Renal replacement therapy at Tx
Peritoneal dialysis2214.6%
Transplantation1 0.7%
None 13 8.6%
Years of pre-transplant dialysis1.93 ± 1.730-8.18
Years on waiting list1061.26 ± 1.120.04-6.25
"/>5 pre-transplant transfusions6241.1%
Current PRA"/>50%/Peak PRA"/>50%16/3310.6/21.9%
CMV serology: neg/pos/unknown114/36/175.5/23.8/0.7%
On Antihypertensiva at time of Tx 1498154.4%
Donor characteristics
Age (year)23.8 ± 14.80.5-54.5
0-4 1811.9%
Gender M/F 15086/64 57.3/43.7%
Weight (kg)12755.5 ± 23.57-101
Donor type
Cause of donor death 117
Donor /Recipient relationships
Donor/Recipient Weight ratio1272.35 ± 1.780.29-8.47
Donor/Recipient BSA ratio1251.70 ± 0.880.21-4.51
Donor/Recipient BMI ratio1251.28 ± 0.280.53-2.15
CMV serology134

Table 2.

Characteristics of the study population

N*Mean ± SD or nRange or %
HLA Mismatch150
HLA-A 0.83 ± 0.60
HLA-B1.03 ± 0.51
HLA-DR0.77 ± 0.55
HLA-ABDR2.62 ± 1.06
Perioperative characteristics
Organ preservation solution149
Cold ischemia time (hours) for DD 11720.34 ± 7.708.40-50.47
"/>30 hr109.3%
Warm ischemia time (min)14838.1 ±.11.815.0-95.0
"/>40 min 5335.8%
Immunosuppression (IS)
Induction 150
Polyclonal (ALS/ATG)92 (43/49)61.3%
Monoclonal (anti-IL2r/OKT3)52 (51/1)34.7%
None 6 4%
Maintenance IS at discharge
Cyclosporine A/Tacrolimus/No104/31/1668.9/20.5/10.6%
Post-transplant characteristics
Tx hospitalization (days)19.3 ± 12.97-113
Delayed graft function(DGF)2516.6%
Acute rejection
Yes vs. No 69/8245.7/54.3 %
Within the first year post Tx 5838.4 %
Beyond the first year post Tx 2315.7 %
Time first rejection episode (days) 46 (10-174)§1-5474
Hemoglobin level at 1 yr (g/dl)13911.5 ± 1.46.4-14.0
Proteinuria ("/>1 g/24 h) at 1 yr 140107.1%
Creatinine Clearance at 1 yr (ml/min/1.73 m2)14072.1 ± 22.014.7-156.5

Table 2. Cont

N=number of transplants for whom data are available; if not specified n=151. §data given as median (interquartile range). CVA: cardiovascular accident; DD: deceased donor; DGF: delayed graft function ; LRD: Living related donor.

3.2. Univariable analysis of factors influencing graft outcome

Table 3 summarizes the predictors of graft outcome in univariable analysis (p<0.10).

Duration of pre-transplant dialysis, multiple blood transfusions pre-transplant (>5), warm ischemia time (superior to 40 min), cold ischemia time, delayed graft function (DGF) and acute rejection were found to significantly affect outcome adversely. Transplants that did not benefit from calcineurin inhibitors had a fourfold increased risk of graft failure (p<0.0001). In addition, over the time of our transplant program, there was a significant lower risk for graft failure with each subsequent year (p=0.008). As far as HLA matching is concerned, two mismatches on HLA-A tended to be detrimental (p=0.064).

Kidney function (creatinine clearance) at 1 year, proteinuria (>1 g/24 h) at 1 year and the level of hemoglobin at 1 year were found to be significant predictors of graft outcome for the transplants that functioned beyond the first year. Risk of graft loss increased with the presence of proteinuria and decreased with an increase in hemoglobin level and an increase in creatinine clearance.

Variables that were not retained as predictors (p>0.10) of graft outcome included among others: primary kidney disease, recipient and donor gender and age, recipient and donor anthropometric parameters (weight, height, BSA, BMI), age ratio and anthropometric parameters ratio between the donor and the recipient, peak and current PRA levels, recipient and donor blood group, donor type, organ preservation solution type, CMV matching status, repeat transplant, and hypertension at transplantation and at 1 year post-transplant.

dfHR95% CIp Value
Time on dialysis (years) 11.171.02-1.340.030
"/>5 Transfusions pre-Tx11.821.12-2.970.016
HLA-A mismatch (2 vs. 0-1)11.960.96-3.980.064
Cold ischemia time (h) (DD)
continue variable11.031.002-1.0650.034
"/>30 h vs. ≤ 30 h12.631.31-5.260.006
Warm ischemia time (min)
as continue variable11.0160.996-1.0370.11
"/>40 min vs. ≤ 40 min11.661.02-2.710.042
Year of transplantation10.950.91-0.990.008
Absence of calcineurin inhibitors14.312.44-7.63<0.0001
Dialysis in the first week post-Tx (DGF) 20.001
Risk graft failure within first 3 months116.893.41-83.800.001
Risk graft failure after first 3 months11.050.54-2.040.88
Acute rejection 12.611.55-4.400.0003
Proteinuria ("/>1 g/24 h) at 1 year 14.132.01-8.480.0001
Hemoglobin at 1 year (g/dl)10.670.54-0.820.0002
Creatinine clearance at 1 year (ml/min/1.73 m2)10.970.95-0.98<0.0001

Table 3.

Predictors of graft outcome in univariable analysis (p<0.10) f: degrees of freedom; HR: hazard ratio; CI: confidence interval

3.3. Multivariable analysis of factors influencing graft outcome

3.3.1. Considering all transplants - graft survival from the time of transplantation

Multivariable Cox regression analysis showed that the significant factors contributing to graft failure were: absence of calcineurin inhibitors, two mismatches on HLA-A, occurrence of acute rejection and occurrence of DGF. The need for dialysis in the first week post-transplant was linked with a very high risk for graft failure within the first three months post-transplant; beyond this period it had no significant impact on graft outcome. The hazard ratios for graft failure and their confidence intervals are given in Table 4. The other factors that were found significant in univariable analysis (multiple pre-transplant transfusions, cold and warm ischemia times, year of transplantation, duration ofpre-transplant dialysis) did not significantly affect outcome when subjected to a multivariable analysis.

dfHR95% CIp Value
Absence of calcineurin inhibitors13.982.15-7.36<0.0001
2 HLA-A mismatches12.771.31-5.840.008
Risk graft failure within first 3 months13.212.62-66.500.002
Risk graft failure after first 3 months 11.310.66- 2.610.44
Acute rejection 12.101.25-3.520.005

Table 4.

Multivariable Cox regression analysis of graft survival from the time of transplantation: analysis of all grafts. ikelihood ratio Chi-square 46.208, df 5, p<0.0001 (n=150)

3.3.2. Considering transplants with ≥ 1 year survival - graft survival after 1 year

This analysis was done on the subset of transplants that were still functioning at 1 year. Nine grafts were lost in the first year. Multivariable Cox regression analysis showed that significant risk factors contributing to graft failure after 1 year were: absence of calcineurin inhibitors, two HLA-A mismatches, kidney function (creatinine clearance) at 1 year, proteinuria at 1 year (superior to 1 g/24 h) and hemoglobin level at 1 year.

The hazard ratios for graft failure and their confidence intervals are given in Table 5.

dfHR95% CIp Value
Absence of calcineurin inhibitors16.733.19-14.21<0.0001
2 HLA-A mismatches13.251.45-7.270.004
Creatinine clearance at 1 yr (ml/min/1.73 m2)10.970.96-0.990.002
Proteinuria ("/>1 g/24 h) at 1 yr13.131.44-6.810.004
Hemoglobin level at 1 yr (g/dl)10.760.61-0.940.011

Table 5.

Multivariable Cox regression analysis of graft survival after 1 year post-transplantation: analysis of grafts that survived beyond the first year. ikelihood ratio Chi-square 52.383, df 5, p<0.0001 (n=139)


4. Discussion

This single center study investigated factors that affect renal transplant outcome in children. Numerous factors concerning recipient characteristics, donor characteristics, perioperative characteristics and post-transplant events were included in the analysis.

Univariable analysis identified a number of factors associated with outcome. Multiple blood transfusions pre-transplant, duration of dialysis pre-transplant, prolonged cold and warm ischemia times, absence of calcineurin inhibitors, occurrence of acute rejection, occurrence of delayed graft function, absence of HLA-A matching, presence of marked proteinuria at 1 year post-transplant were associated with poor outcome. Risk of graft failure decreased with higher creatinine clearance at 1 year, higher level of hemoglobin at 1 year and later year of entry in the transplant program. Certainly in term of single variable determinants, these specific factors appear familiar to professionals in renal transplantation.

The following factors remained of significance after multivariable analysis: use of calcineurin inhibitors, absence of HLA-A matching, delayed graft function defined as the need for dialysis in the first week post-transplant, occurrence of acute rejection, proteinuria superior to 1 g/24 h at 1 year, hemoglobin level at 1 year and kidney function at 1 year.

Transplants that did not benefit from calcineurin inhibitors had a fourfold increased risk of graft failure. Most of these transplants (14 of 16) were performed in the period 1980-1984 before CsA was introduced. As the period 1980-1984 represents also the first years of our pediatric transplant program, the lack of center experience, the so called learning curve, may be partly a confounding factor. We found CsA to impact significantly and independently both on early and long term graft survival. This is similar to the findings of two single center pediatric studies (Chavers et al., 1994; Offner et al., 1999) reporting a beneficial effect of CsA up to 5 and 8 years post-transplant. The introduction of CsA in the mid-1980s for the prevention of acute rejection has been a major breakthrough in the transplantation field. However it has been reported to impact mostly on early graft survival by lowering acute rejection rates; its effect on long term outcome being much more controversial (Chapman & Nankivell, 2006; Pascual et al., 2002; Schurman & McEnery, 1997). One of the major concerns for long term outcome is the calcineurin inhibitor-induced chronic nephrotoxicity leading to progressive nephron loss and declining renal transplant function (Chapman & Nankivell, 2006; Nankivell et al., 2004). Hence with the broadening of the immunosuppressive drugs arsenal, calcineurin inhibitor minimization, calcineurin inhibitor withdrawal or avoidance strategies have been developed. Calcineurin inhibitor withdrawal and avoidance protocols have been associated with an amelioration of the renal function, however at the cost of a higher rejection rates (Guerra et al., 2007; Höcker & Tönshoff, 2011). The long-term safety and efficacy of calcineurin inhibitor withdrawal and avoidance strategies need to be further validated in controlled clinical trials. At present the safest therapeutic strategy for pediatric renal allograft with chronic calcineurin inhibitor induced nephrotoxicity appears to be a mycophenolate based regimen with low dose calcineurin inhibitor and corticosteroids (Höcker & Tönshoff, 2011).

Two HLA-A mismatches was in our population a strong predictive risk factor for graft failure. Matching for HLA-DR and HLA-B has generally received priority over matching for HLA-A in children as well as in adults. Multivariable analysis of the data from the large NAPRTCS registry showed that the absence of HLA-B match and the absence of HLA-DR match were significant risk factors for graft failure (NAPRTCS, 2010). Roberts and colleagues reported that matching at the HLA-DR locus has significant effect on the survival of renal grafts from DD whereas matching at the HLA-A and B loci has only small effect (Roberts et al., 2004). However, Zantvoort and colleagues from Eurotransplant (Zantvoort et al., 1996) found an independent HLA-A matching effect on long term survival of DD kidney grafts with an increasing effect over time (up to 6 years post-transplant). This was in contrast to the strong, short-lived, effects of HLA-DR and -B matching, which could only be detected up to 6 months and 2 years after transplantation, respectively. A clear additive beneficial effect of HLA-A matching was shown in the group without B and DR mismatches. They concluded that prospective matching for the HLA-A antigens remains important for renal allograft survival and our data are in agreement with this. Data from the Collaborative Transplant Study indicated that class II HLA-DR locus has a stronger impact than the class I HLA-A and HLA-B loci during the first post-transplant year but that during subsequent years the three loci have an equivalent and additive influence on graft survival: to obtain optimal long term survival all three loci must be considered in the donor-recipient matching procedure (Opelz et al., 1999). This has been our policy through the years of our program as reflected by the very low percentage of transplants with more than 3 HLA-A,-B,-DR mismatches (14%). Obtaining the best possible HLA match for children is also an important part of the Eurotransplant allocation process. In contrast, in the United States, matching for HLA-A and –B has been abandoned and only HLA-DR is considered during the kidney allocation process. Based on an retrospective analysis of the UNOS registry data from 1585 pediatric recipients of DD kidney between 1996-2004 showing no advantage for HLA-DR matching, it has been recommended that, in the modern era of immunosuppression, the HLA match should be entirely disregarded when allocating donor kidneys to pediatric recipients (Gritsch et al., 2008). This will allow shortening the waiting time on dialysis for children. This view has been challenged in a recent report by Opelz and Döhler who examined the outcomes of 9209 pediatric recipients of DD kidneys from the CTS registry (Opelz & Döhler, 2010). Comparing two decades (1988-1997 and 1998-2007), they showed that, although overall graft survival improved over time, HLA matching remained highly significant and similarly strong despite the introduction of newer and more potent immunosuppression. A hierarchical relationship was observed for the effect of increasing number of mismatches on graft survival in both periods. Interestingly, they found a strong association between two HLA-DR mismatches and non Hodgkin lymphoma, and recommended therefore to avoid transplants with 2 HLA-DR mismatches.

In our view, a well matched first kidney is especially important in children as they have a high likelihood of needing more than one transplant during their lifetime. A poor matched kidney is more likely to result in HLA allosensitization, resulting therefore in long waiting time for a second transplant when the first graft fails and compromising the chance of a successful retransplantation (Meier-Kriesche et al., 2009).

The need for dialysis in the first week after transplantation carried in our transplant population a very high risk of graft failure within the first months post-transplant but did not impact significantly on the long term outcome. Similar findings emerged out of the analysis of the NAPRTCS registry (Tejani et al., 1999). DGF was found to be a significant independent predictor of graft failure. However, when patients whose grafts had failed during the first year were censored, no differences in graft survival were noted between patients with and without DGF for either LRD or DD recipients. Similarly DGF was not an independent predictor of long term graft survival in a large single center analysis of pediatric renal recipients (Vats et al., 2002). Good long term graft survival has also been obtained with non-heart-beating donors despite a higher incidence of DGF (Koffman & Gambaro, 2003; Sanchez-Fructuoso et al., 2004; Summers et al., 2010). Others have reported a negative influence of DGF on long term graft outcome (Gjertson, 2000; Moreira et al., 2011). It remains however difficult to determine whether this negative impact of DGF is independent of two associated known risk factors for long-term outcome: acute rejection (AR) and degree of kidney function (Geddes et al., 2002; Troppmann et al., 1996). The combination of DGF and AR seems to be the most detrimental for graft survival (Matas et al., 2000; McLaren et al., 1999).

The occurrence of acute rejection was an independent predictor of graft survival when all transplants were included in the analysis. When only the grafts that functioned beyond the first year were considered, acute rejection disappeared from the significant factors in the multivariable analysis. The lack of significance can be due to the reduced power as acute rejection was introduced as a time dependent covariate and most of the events (acute rejection) occurred within the first year.

Acute rejection is an important predictor of chronic rejection which is the most common cause of graft loss. Single and multicenter studies in adult and children have shown an association between acute rejection and subsequent development of chronic rejection (Dart et al., 2010; Matas, 2000; Tejani & Sullivan, 2000). It is therefore expected that a reduction in the incidence of acute rejection - in our program the incidence of acute rejection in the period 2000-2010 has dropped to 7% - should result in the reduction of chronic rejection and thus in better long term graft survival. This is supported by a NAPRTCS study (Tejani et al., 2002). Moreover some studies clearly indicate that a rejection free milieu can truly provide improved long term survival. Vats et al. in one of the largest single center study to date on long term graft outcome in pediatric renal transplant patients found freedom from acute rejection in the first year post-transplant to be the strongest independent predictor of improved graft survival (Vats et al., 2002). In an analysis of the UNOS data on 93934 adult patients, Hariharan et al. reported an increase in graft half-life from 11.9 years for patients with an episode of clinical acute rejection during the first year post-transplant to 27.1 years for those who did not have such an episode (Hariharan et al., 2000). Meier-Kriesche group, on the contrary, reported that the significant reduction in the acute rejection rates observed in the modern era has resulted in a marked improvement of the short term graft survival but in negligible progress in longer term survival as the attrition rate beyond the first year show little improvements (Lamb et al., 2011; Meier-Kriesche et al., 2004).

We found kidney function at 1 year to be an independent predictor of long term graft survival indicating that preservation of renal function during the first year is important and that events occurring within the first year impacting on this function are of critical importance for long term survival. Several authors have reported that renal function after transplantation has a strong impact on long term graft survival. Hariharan et al. analysing factors influencing graft survival for 105742 adult renal transplants between 1988 and 1998 reported one year creatinine and delta creatinine 6 months-1 year values to be the best predictors of long term survival and that the recent improvement in graft half-lives are related to conservation of renal function within the first year post-transplant (Hariharan et al., 2002). As it is the case in our study, when renal function within the first year and clinical acute rejection were included in their model for long term graft failure it was the creatinine at 1 year that was significant and not clinical acute rejection. Thus in the setting of acute rejection it is the preservation of renal function that is more important for graft survival. Data from a multicenter study pointed the 1 year estimated glomerular filtration rate to be the most relevant predictor of long term graft function. The impact of DGF and acute rejection on the long term graft function appeared to be fully mediated by their influence on the 1 year GFR (Salvadori et al., 2006). Similar to us, three studies found allograft function at 1 year to be a significant and independent predictor of graft outcome in children (Filler et al., 2002; Mitsnefes et al., 2003; Muscheites et al., 2009). Kidney function at one year might be thus a useful surrogate end point for renal transplant clinical trials in children.

Anemia is a significant complication of renal failure being associated with numerous adverse outcomes, including compromised renal and cardiac function, cardiovascular disease, decreased exercise tolerance, cognitive impairment, poorer quality of life, increased risk for hospitalization and mortality (Koshy & Geary, 2008; Warady & Ho, 2003). Anemia is expected to resolve after transplantation. More and more data indicate on the contrary that anemia is a common phenomenon in pediatric kidney recipients with reported prevalence rates ranging from 25% to 80% depending on the definition of anemia used and the time post-transplantation (Al-Khoury et al., 2006; Mitsnefes et al., 2005; Yorgin et al., 2002). The prevalence of anemia at 1 year (defined as hemoglobin level <11 g/dl (Al-Khoury et al., 2006; Mitsnefes et al., 2005)) was 30% among our transplanted children. The pathogenesis of post-transplant anemia is multifactorial and include iron deficiency, bone marrow suppression effects of immunosuppressive medications and other therapeutic agents, chronic inflammatory conditions caused by infections, frequent blood draws, and deteriorating renal function (Al-Uzri et al., 2003). In our multivariable analysis, hemoglobin level at 1 year post-transplant was a significant predictor of long term graft outcome, a higher level of hemoglobin being associated with a lower risk of graft failure. When hemoglobin was dichotomized at 11 g/dl, the HR for anemia in the multivariable model was 1.93 (p=0.024; 95% CI 1.09-3.42) while the HRs of the other covariates (table 5) remained in the same order of magnitude (data not shown). It was significant in the presence of “kidney function” indicating that anemia is just not merely a surrogate marker of a declining function of the allograft. Anemia is an independent risk factor for progression of renal failure in pre-dialysis adults (Kovesdy et al., 2006) and treating anemia slows down the decline of kidney function in these patients (Gouva et al., 2004). Our findings are in line with several studies in the adult population showing post-transplant anemia to be associated with increased risk for subsequent graft loss (Chhabra et al., 2008; Imoagene-Oyedeji et al., 2006; Kamar & Rostaing, 2008; Molnar et al., 2007). In these studies, anemia was also associated with impaired patient survival and with a higher proportion of cardiovascular deaths. Whether this is also the case in children remains to be determined but a cross sectional study of pediatric kidney recipients pointing anemia to be predictive of left ventricular hypertrophy - an independent predictor of cardiovascular morbidity and mortality in adults - raises concern. Post-transplant anemia has also been reported to impact on the quality of life; anemic children presenting more physical discomfort (Riano-Galan et al., 2009). For all these reasons including our findings that anemia predicts poorer graft survival, anemia deserves to be recognized early after transplantation, properly investigated and corrected.

The presence of marked proteinuria at 1 year was in our study population a strong and independent predictor of impaired graft outcome. This is in good agreement with several studies in adults showing increasing levels of proteinuria at 1 year post-transplant to be associated with increasing risk of graft failure (Amer et al., 2007; Fernandez-Fresnedo et al., 2004; Roodnat et al., 2001). Persistent proteinuria is also associated in these studies with increased mortality. In our population, persistent proteinuria was attributed to biopsy proven chronic allograft nephropathy, recurrence of primary kidney disease (FSGS and dense deposit disease) and de novo glomerulonephritis; this is in line with reports in adult kidney recipients (Barama, 2008). The underlying cause of proteinuria and not the proteinuria per se could thus be the factor contributing to transplant dysfunction and failure. However it is now recognized that proteinuria is not only a sensitive marker of renal disease but is directly damaging to the kidney by various mechanisms including direct mesangial toxicity, tubular overload, induction of a proinflammatory state and release of substances associated with the development of fibrogenesis and glomerulosclerosis (Baines & Brunskill, 2008). Recent reports indicate that even early (1-3 months post-transplant) very low (<0.5 g/24 h) and low grade (<1 g/24 h) proteinuria - often referred as ‘subclinical’ or ‘negligible’ - is a potent predictor of graft loss in adult kidney recipients and that short term reduction in proteinuria is associated with improved long term graft survival (Halimi et al., 2005; Sancho Calabuig et al., 2009).

While ACE inhibitors have been shown to be effective and safe in proteinuric adult kidney recipients (Barama, 2008; Hiremath et al., 2007), there is a paucity of data in the pediatric transplant population. In one retrospective study, children treated with ACEI had slightly lower proteinuria than those who did not receive such treatment (Arbeiter et al., 2004). A recent uncontrolled small prospective study showed a reduction of proteinuria in nearly all children treated with ACEI (Seeman et al., 2010).

Several factors such as donor source, donor age, recipient age and hypertension were in contrast with the literature not found significant in our study.

Large registry and single centers studies show better graft survival for recipients of LRD as compared to recipient of DD kidney (Gjertson & Cecka, 2001; Magee et al., 2008; NAPRTCS, 2010). Data from the NAPRTCS indicate that the 1 year graft survival obtained with deceased donors has reached that of the living donors. In our population, graft survival is also equivalent with both donor sources at 1 year and thereafter superior for LRD. However, this difference is not statistically significant, possibly because of the small number of LRD recipients. Another explanation is that we achieved good survival rates with the DD recipients, due to our strict policy of donor selection, good HLA matching and short ischemia times.

There are a number of reports indicating poorer results with kidney from young donors, essentially due to an increase incidence of vascular thrombosis, primary non function and other technical causes (Cransberg et al., 2000; Postlethwaite et al., 2002; Seikaly et al., 2001). Earlier NAPRCTS reports of poor graft survival with young donors have led to a constant decrease of the use of these donors in pediatric recipients: donor younger than 10 years represented 38% of the DD for pediatric recipients in the 1988 cohort, 13% in the 2000 cohort, 8% in the 2005 cohort and less than 5% in the 2009 cohort (NAPRTCS, 2010). We have obtained good results with young deceased donors with short and long term survival comparable to older donor (Van Damme-Lombaerts et al., 2001). Data indicate also that pediatric donor organs perform better than adult donor organs in pediatric patients (Nashan, 2004; Pape et al., 2004) and it seems thus justify that pediatric donors should preferentially be allocated to pediatric recipients. This might be stimulated by a very recent analysis of the NAPRTCS registry showing comparable 3-year graft survival and comparable kidney function in recipient of young donors (Moudgil et al., 2011).

Young recipient age (<5 yr) has been traditionally associated with poorer short term graft survival due to a high incidence of vascular thrombosis, technical complications and acute rejection (Cransberg et al., 2000; Gagnadoux et al., 1993; Kari et al., 1999; Postlethwaite et al., 2002). However, there are a few single center reports, including ours, indicating that excellent renal transplantation results can be obtained in this high risk group of patients with careful and meticulous surgical techniques, vigilant management of fluids administration, use of low molecular weight heparin in the early postoperative period and close monitoring of immunosuppression with early diagnosis and treatment of rejection (Gagnadoux et al., 1993; Ojogho et al., 2002; Vats et al., 2002). Furthermore, past the first post-transplant year, graft survival in these youngest children has been reported to be excellent: as good or even superior to older children and adults (Gjertson & Cecka, 2001; Ojogho et al., 2002; Vats et al., 2002).

In our study hypertension was not a significant predictor of graft failure. This may be due to the fact that we relied on the use of antihypertensive medications and their numbers as surrogates for defining hypertension and its severity. Studies using actual blood pressure measurements found early post-transplant hypertension to be a significant and independent predictor of early allograft function and long term graft outcome in pediatric renal transplant recipients (Mitsnefes et al., 2003; Mitsnefes et al., 2001).


5. Conclusion

Despite its limitation due to the small number of patients, our study shows that several factors influence the outcome of renal allograft in our pediatric population. The introduction of CsA had a very significant impact in improving graft survival. A good HLA match remains important and matching for HLA-A locus in children should not be neglected. Early recognition, investigation and treatment of post-transplant anemia and proteinuria may play an important role in ultimately improving outcomes.

Prevention and adequate management of DGF, prevention and effective treatment of acute rejection episodes, therapeutic monitoring of calcineurin inhibitors to limit their nephrotoxicity, prevention of other injuries to the allograft by factors such as severe infection, hypertension, obstruction should contribute to the preservation of the renal function during the first year and lead to improved long term outcome.



We are very grateful to Dr. Steffen Fieuws from the Department of Biostatistics for his help with statistical analysis.


  1. 1. Al-KhouryS.ShahN.AfzaliB.CovicA.TaylorJ.GoldsmithD. 2006 Post-transplantation anaemia in adult and paediatric renal allograft recipients-Guy’s Hospital experience. Nephrol Dial Transplant, 21 7 (July 2006), 19741980 , 0931-0509
  2. 2. Al-UzriA.YorginP. D.KlingP. J. 2003 Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatric Transplantation, 7 4 (August 2003), 253264 , 1397-3142
  3. 3. AmerH.FidlerM. E.MyslakM.MoralesP.KremersW. K.LarsonT. S.StegallM. D.CosioF. G. 2007 Proteinuria After Kidney Transplantation, Relationship to Allograft Histology and Survival. American Journal of Transplantation, 7 12 (December 2007), 27482756 , 1600-6143
  4. 4. ArbeiterK.PichlerA.StembergerR.MuellerT.RuffingshoferD.VarghaR.BalzarE.AufrichtC. 2004 ACE inhibition in the treatment of children after renal transplantation. Pediatric Nephrology, 19 2 (February 2004), 222226 , 0093-1041X
  5. 5. BainesR. J.BrunskillN. J. 2008 The molecular interactions between filtered proteins and proximal tubular cells in proteinuria. Nephron Exp Nephrol, 110 2 (November 2008), e67e71 , 1660-2129
  6. 6. BaramaA. A. 2008 Mechanisms and Management of Proteinuria in Kidney Transplant Patients. Drugs, 68 No. Suppl.1, 3339 , 0012-6667
  7. 7. BenfieldM. R.Mc DonaldR.SullivanE. K.StableinD. M.TejaniA. 1999 The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric Transplantation, 3 2 (May 1999), 152167 , 1397-3142
  8. 8. ChapmanJ. R.NankivellB. J. 2006 Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? Nephrology Dialysis Transplantation, 21 8 (August 2006), 20602063 , 0931-0509
  9. 9. ChaversB. M.KimE. M.MatasA. J.GillinghamK. J.NajarianJ. S.MauerS. M. 1994 Causes of kidney allograft loss in a large pediatric population at a single center. Pediatric Nephrology, 8 1 (February 1994), 5761 , 0093-1041X
  10. 10. ChhabraD.GrafalsM.SkaroA. I.ParkerM.GallonL. 2008 Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection. Clinical Journal of the American Society of Nephrology, 3 4 (July 2008), 11681174 , 1555-9041
  11. 11. CransbergK.van GoolJ. D.DavinJ. C.De JongM. C. J.DarbyM.BoendermakerM. E.De MeesterJ. M. J.StijnenT.WolffE. D.NautaJ. 2000 Pediatric renal transplantation in the Netherlands. Pediatric Transplantation, 4 1 (February 2000), 7281 , 1397-3142
  12. 12. DartA. B.SchallA.GibsonI. W.Blydt-HansenT. D.BirkP. E. 2010 Patterns of Chronic Injury in Pediatric Renal Allografts. Transplantation, 89 3 (February 2010), 334340 , 0041-1337
  13. 13. Fernandez-FresnedoG.PlazaJ. J.Sanchez-PlumedJ.Sanz-GuajardoA.Palomar-FontanetR.AriasM. 2004 Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrology Dialysis Transplantation, 19 No. suppl 3, (June 2004), iii47iii51 , 0931-0509
  14. 14. FillerG.TrompeterR.WebbN. J.WatsonA. R.MilfordD. al. 2002 One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. Transplantation Proceedings, 34 5 (August 2002), 19351938 , 0041-1345
  15. 15. GagnadouxM. F.CharbitM.BeurtonD.RevillonY.NiaudetP.BroyerM. 1993 Renal transplantation in children under five years of age. Experience at the Hopital des Enfants-Malades. Annales de Pediatrie (Paris), 40 2 (February 1993), 108111 , 0066-2097
  16. 16. GeddesC. C.WooY. M.JardineA. G. 2002 The impact of delayed graft function on the long-term outcome of renal transplantation. Journal of Nephrology, 15 1 (January-February 2002), 1721 , 1121-8428
  17. 17. GjertsonD. W. 2000 Impact of delayed graft function and acute rejection on kidney graft survival. Clinical Transplantation, 467480 , 0902-0063
  18. 18. GjertsonD. W.CeckaJ. M. 2001 Determinants of long-term survival of pediatric kidney grafts reported to the United Network for Organ Sharing kidney transplant registry. Pediatric Transplantation, 5 1 (February 2001), 515 , 1397-3142
  19. 19. GouvaC.NikolopoulosP.IoannidisJ. P.SiamopoulosK. C. 2004 Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney International, 66 2 (August 2004), 753760 , 0085-2538
  20. 20. GritschH. A.VealeJ. L.LeichtmanA. B.GuidingerM. K.MageeJ. C.Mc DonaldR. A.HarmonW. E.DelmonicoF. L.EttengerR. B.CeckaJ. M. 2008 Should Pediatric Patients Wait for HLA-DR-Matched Renal Transplants? American Journal of Transplantation, 8 10 (October 2008), 20562061 , 1600-6143
  21. 21. GuerraG.SrinivasT. R.Meier-KriescheH.U. 2007 Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transplant International, 20 10 (October 2007), 813827 , 0934-0874
  22. 22. HalimiJ.M.LaouadI.BuchlerM.Al-NajjarA.ChateletV.HoussainiT. S.NivetH.LebranchuY. 2005 Early Low-Grade Proteinuria: Causes, Short-Term Evolution and Long-Term Consequences in Renal Transplantation. American Journal of Transplantation, 5 9 (September 2005), 22812288 , 1600-6143
  23. 23. HariharanS.JohnsonC. P.BresnahanB. A.TarantoS. E.Mc IntoshM. J.StableinD. 2000 Improved graft survival after renal transplantation in the United States, 1988 to 1996. New England Journal of Medicine, 342 9 (March 2000), 605612 , 1533-4406
  24. 24. HariharanS.Mc BrideM. A.CherikhW. S.TollerisC. B.BresnahanB. A.JohnsonC. P. 2002 Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney International, 62 1 (July 2002), 311318 , 0085-2538
  25. 25. HiremathS.FergussonD.DoucetteS.MulayA. V.KnollG. A. 2007 Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. American Journal of Transplantation, 7 10 (October 2007), 23502360 , 1600-6135
  26. 26. HöckerB.TönshoffB. 2011 Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Paediatr Drugs, 13 1 (February 2011), 4969 , 1174-5878
  27. 27. HwangA. H.ChoY. W.CicciarelliJ.MentserM.IwakiY.HardyB. E. 2005 Risk Factors for Short- and Long-term Survival of Primary Cadaveric Renal Allografts in Pediatric Recipients: A UNOS Analysis. Transplantation, 80 4 (August 2005), 466470 , 0041-1337
  28. 28. Imoagene-OyedejiA. E.RosasS. E.DoyleA. M.GoralS.BloomR. D. 2006 Posttransplantation Anemia at 12 Months in Kidney Recipients Treated with Mycophenolate Mofetil: Risk Factors and Implications for Mortality. Journal of the American Society of Nephrology, 17 11 (November 2006), 32403247 , 1046-6673
  29. 29. KamarN.RostaingL. 2008 Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation, 85 8 (April 2008), 11201124 , 0041-1337
  30. 30. KariJ. A.RomagnoliJ.DuffyP.FernandoO. N.ReesL.TrompeterR. S. 1999 Renal transplantation in children under 5 years of age. Pediatric Nephrology, 13 9 (November 1999), 730736 , 0093-1041X
  31. 31. KoffmanG.GambaroG. 2003 Renal transplantation from non-heart- beating donors: a review of the European experience. Journal of Nephrology, 16 3 (May-June 2003), 334341 , 1121-8428
  32. 32. KoshyS.GearyD. 2008 Anemia in children with chronic kidney disease. Pediatric Nephrology, 23 2 (February 2008), 209219 , 0093-1041X
  33. 33. KovesdyC. P.TrivediB. K.Kalantar-ZadehK.AndersonJ. E. 2006 Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney International, 69 3 (February 2006), 560564 , 0085-2538
  34. 34. LambK. E.LodhiS.Meier-KriescheH. U. 2011 Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal. American Journal of Transplantation, 11 3 (March 2011), 450462 , 1600-6143
  35. 35. MageeJ. C.KrishnanS. M.BenfieldM. R.HsuD. T.ShneiderB. L. 2008 Pediatric Transplantation in the United States, 1997-2006. American Journal of Transplantation, 8 4p2 (August 2008), 935945 , 1600-6143
  36. 36. MatasA. J. 2000 Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients. Pediatric Transplantation, 4 2 (May 2000), 9299 , 1397-3142
  37. 37. MatasA. J.GillinghamK. J.HumarA.DunnD. L.SutherlandD. E.NajarianJ. S. 2000 Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. Transplantation, 69 1 (January 2000), 5458 , 0041-1337
  38. 38. Mc LarenA. J.JassemW.GrayD. W.FuggleS. V.WelshK. I.MorrisP. J. 1999 Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clinical Transplantation, 13 3 (June 1999), 266272 , 0902-0063
  39. 39. Meier-KriescheH.U.ScornikJ. C.SusskindB.RehmanS.ScholdJ. D. 2009 A Lifetime Versus a Graft Life Approach Redefines the Importance of HLA Matching in Kidney Transplant Patients. Transplantation, 88 1 (July 2009), 2329 , 0041-1337
  40. 40. Meier-KriescheH. U.ScholdJ. D.SrinivasT. R.KaplanB. 2004 Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American Journal of Transplantation, 4 3 (March 2004), 378383 , 1600-6143
  41. 41. MitsnefesM. M.KhouryP. R.Mc EneryP. T. 2003 Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients. The Journal of Pediatrics, 143 1 (July 2003), 98103 , 0022-3476
  42. 42. MitsnefesM. M.OmolojaA.Mc EneryP. T. 2001 Short-term pediatric renal transplant survival: blood pressure and allograft function. Pediatric Transplantation, 5 3 (June 2001), 160165 , 1397-3142
  43. 43. MitsnefesM. M.Subat-DezulovicM.KhouryP. R.GoebelJ.StrifeC. F. 2005 Increasing incidence of post-kidney transplant anemia in children. American Journal of Transplantation, 5 7 (July 2005), 17131718 , 1600-6135
  44. 44. MolnarM. Z.CziraM.AmbrusC.SzeifertL.SzentkiralyiA.BekoG.RosivallL.RemportA.NovakM.MucsiI. 2007 Anemia Is Associated with Mortality in Kidney-Transplanted Patients-A Prospective Cohort Study. American Journal of Transplantation, 7 4 (April 2007), 818824 , 1600-6143
  45. 45. MoreiraP.áS.H.FigueiredoA.MotaA. 2011 Delayed Renal Graft Function: Risk Factors and Impact on the Outcome of Transplantation. Transplantation Proceedings, 43 1 (January 2011), 100105 , 0041-1345
  46. 46. MoudgilA.MartzK.StableinD. M.PuliyandaD. P. 2011 Good outcome of kidney transplants in recipients of young donors: a NAPRTCS data analysis. Pediatric Transplantation, 15 2 (March 2011), 167171 , 1397-3142
  47. 47. MuscheitesJ.WiggerM.DruecklerE.KlaassenI.JohnU.WygodaS.FischerD.C.KundtG.MisselwitzJ.Mü 2009 Estimated one-yr glomerular filtration rate is an excellent predictor of long-term graft survival in pediatric first kidney transplants. Pediatric Transplantation, 13 (May 2009), 365370 , 1397-3142
  48. 48. NankivellB. J.BorrowsR. J.FungC. L.S.O’ConnellP. J.ChapmanJ. R.AllenR. D. M. 2004 Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology. Transplantation, 78 4 (August 2004), 557565 , 0041-1337
  49. 49. NAPRTCS. 2010 NAPRTCS 2010 Annual Transplant Report,14.04.2011, Available from
  50. 50. NashanB. 2004 Renal allograft allocation for children: are we penalizing children to not penalize adults? Transplantation, 77 8 (April 2004), 11451146 , 0041-1337
  51. 51. OffnerG.LattaK.HoyerP. F.BaumH. J.EhrichJ. H.PichlmayrR.BrodehlJ. 1999 Kidney transplanted children come of age. Kidney International, 55 4 (April 2004), 15091517 , 0085-2538
  52. 52. OjoghoO.SahneyS.CutlerD.AbdelhalimF.HasanM.BaronP.ConcepcionW. 2002 Superior long-term results of renal transplantation in children under 5 years of age. Am Surg, 68 12 (December 2002), 11151119 , 0002-9610
  53. 53. OpelzG.DöhlerB. 2010 Pediatric Kidney Transplantation: Analysis of Donor Age, HLA Match, and Posttransplant Non-Hodgkin Lymphoma: A Collaborative Transplant Study Report. Transplantation, 90 3 (August 2010), 292297 , 0041-1337
  54. 54. OpelzG.WujciakT.DohlerB.SchererS.MytilineosJ. 1999 HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet, 1 3 334342 , 1398-1714
  55. 55. PapeL.OffnerG.EhrichJ. BoerJ.PersijnG. G. 2004 Renal allograft function in matched pediatric and adult recipient pairs of the same donor. Transplantation, 77 8 (April 2004), 11911194 , 0041-1337
  56. 56. PascualM.TheruvathT.KawaiT.Tolkoff-RubinN. .CosimiA. B. 2002 Strategies to Improve Long-Term Outcomes after Renal Transplantation. New England Journal of Medicine, 346 8 (February 2002), 580590 , 1533-4406
  57. 57. PostlethwaiteR. J.JohnsonR. J.ArmstrongS.BelgerM. A.FuggleS. V.MartinS.MiddletonD.RayT. C.RigdenS. al. 2002 The outcome of pediatric cadaveric renal transplantation in the UK and Eire. Pediatric Transplantation, 6 5 (October 2001), 367377 , 1397-3142
  58. 58. Riano-GalanI.MalagaS.RajmilL.AricetaG.NavarroM.LorisC.ValloA. 2009 Quality of life of adolescents with end-stage renal disease and kidney transplant. Pediatric Nephrology, 24 8 (August 2009), 15611568 , ISSN 0931-041X
  59. 59. RobertsJ. P.WolfeR. A.Bragg-GreshamJ. L.RushS. H.WynnJ. J.DistantD. A.AshbyV. B.HeldP. J.PortF. K. 2004 Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. New England Journal of Medicine, 350 6 (February 2004), 545551 , 1533-4406
  60. 60. RoodnatJ. I.MulderP. G.Rischen-VosJ.van RiemsdijkI. C.van GelderT.ZietseR.WeimarJ. N. I. J. .W. 2001 Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation, 72 3 (August 2001), 438444 , 0041-1337
  61. 61. al. 2006 Estimated One-Year Glomerular Filtration Rate is the Best Predictor of Long-term Graft Function Following Renal Transplant. Transplantation, 81 2 (January 2006), 202206 , 0041-1337
  62. 62. Sanchez-FructuosoA.PratsSanchez. D.MarquesVidas. M.Lopez DeNovales. E.BarrientosGuzman. A. 2004 Non-heart beating donors. Nephrol Dial Transplant, 19 Suppl. 3, (June 2004), iii26iii31 , 0931-0509
  63. 63. SanchoCalabuig. A.PallardóMateu. L. M.AvilaBernabeu. A. I.GavelaMartínez. E.BeltránCatalán. S.CrespoAlbiach. J. F. 2009 Very Low-Grade Proteinuria at 3 Months Posttransplantation Is an Earlier Marker of Graft Survival. Transplantation Proceedings, 41 6 (August 2009), 21222125 , 0041-1345
  64. 64. SchurmanS. J.Mc EneryP. T. 1997 Factors influencing short-term and long-term pediatric renal transplant survival. J Pediatr, 130 3 (March 1997), 455462 , 0022-3476
  65. 65. SeemanT.DušekJ.VondrákK.JandaJ. 2010 Ramipril in the treatment of proteinuria in children after renal transplantation. Pediatric Transplantation, 14 2 (August 2009), 283287 , 1397-3142
  66. 66. SeikalyM.HoP. L.EmmettL.TejaniA. 2001 The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatric Transplantation, 5 3 (June 2001), 215231 , 1397-3142
  67. 67. SummersD. M.JohnsonR. J.AllenJ.FuggleS. V.CollettD.WatsonC. J.BradleyJ. A. 2010 Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. The Lancet, 376 9749 (October 2010), 13031311 , 0140-6736
  68. 68. TejaniA.HoP. L.EmmettL.StableinD. M. 2002 Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). American Journal of Transplantation, 2 2 (February 2002), 142147 , 0041-1337
  69. 69. TejaniA.SullivanE. K. 2000 The impact of acute rejection on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatric Transplantation, 4 2 (May 2000), 107111 , 0041-1337
  70. 70. TejaniA. H.SullivanE. K.AlexanderS. R.FineR. N.HarmonW. E.KohautE. C. 1999 Predictive factors for delayed graft function (DGF) and its impact on renal graft survival in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric Transplantation, 3 4 (November 1999), 293300 , 1397-3142
  71. 71. TroppmannC.GillinghamK. J.GruessnerR. W.DunnD. L.PayneW. D.NajarianJ. S.MatasA. J. 1996 Delayed graft function in the absence of rejection has no long-term impact. A study of cadaver kidney recipients with good graft function at 1 year after transplantation. Transplantation, 61 9 (May 1996), 13311337 , 0041-1337
  72. 72. Van Damme-LombaertsR.HermanJ.CoosemansW.PirenneJ. 2001 Pediatric renal transplantation: a single Belgian center experience over 20 years. Pediatric Transplantation, 5 6 (December 2001), 447451 , 1397-3142
  73. 73. VatsA.GillinghamK.MatasA.ChaversB. 2002 Improved late graft survival and half-lives in pediatric kidney transplantation: a single center experience. American Journal of Transplantation, 2 10 (November 2002), 939945 , 1600-6143
  74. 74. WaradyB.HoM. 2003 Morbidity and mortality in children with anemia at initiation of dialysis. Pediatric Nephrology, 18 10 (October 2003), 10551062 , 0093-1041X
  75. 75. YorginP. D.BelsonA.SanchezJ.AlUzri. A. Y.SarwalM.BlochD. A.OehlertJ.SalvatierraO.AlexanderS. R. 2002 Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis, 40 6 (December 2002), 13061318 , 0272-6386
  76. 76. ZantvoortF. A.D’AmaroJ.PersijnG. G.CohenB.SchreuderG. M.Van RoodJ. J.ThorogoodJ. 1996 The impact of HLA-A matching on long-term survival of renal allografts. Transplantation, 61 5 (March 1996), 841844 , 0041-1337

Written By

Jean Herman and Rita Van Damme-Lombaerts

Submitted: 21 October 2010 Published: 17 August 2011